GEOGRAPHIC INFORMATION AND CUSTOMER CONCENTRATION:

Geographic Information

The Company and its subsidiaries are engaged in one line of business, the development, licensing and sale of pharmaceutical products. The Company conducts its international business through its Bermuda subsidiary which contracts with various manufacturers located in the United Kingdom, Switzerland and Italy, to make product for both its international and domestic operations. Most arrangements with licensees are made by the Bermuda company. These customers sell their products into several countries. The Company’s two largest international customers have been Merck Serono and Lil’ Drug Store.

The following table shows selected information by geographic area:



	Revenues		Profit (Loss) from Operations			Identifiable Assets
As of and for the year ended December 31, 2012-
United States	$	8,566,725	$	(3,784,230	)	$	31,967,418
Switzerland	17,261,652		6,593,738			1,189,183
Other	—		—			3,781,080
Subtotal International	17,261,652		6,593,738			4,970,263
Total	$	25,828,377	$	2,809,508		$	36,937,681

As of and for the year ended December 31, 2011-
United States	$	28,420,480	$	17,761,438		$	26,588,480
Switzerland	14,641,541		5,167,424			5,149,384
Other	—		—			4,344,722
Subtotal International	14,641,541		5,167,424			9,494,106
Total	$	43,062,021	$	22,928,862		$	36,082,586

As of and for the year ended December 31, 2010-
United States	$	33,281,893	$	(5,837,836	)	$	23,344,803
Switzerland	10,353,058		7,011,629			4,187,637
Other	2,041,346		—			2,326,402
Subtotal International	12,394,404		7,011,629			6,514,039
Total	$	45,676,297	$	1,173,793		$	29,858,842

Customer Concentration -

The following table presents information about Columbia’s revenues by customer, including royalty and license revenue for the three years ended December 31:



	2012		2011			2010
Merck Serono	17,215,126		14,627,491			10,353,058
Actavis	8,061,253		27,826,678			20,122,930
Lil' Drug Store Products, Inc.	505,473		445,149			3,787,133
Cardinal Healthcare	—		232,470			3,729,885
McKesson	—		229,887			3,130,158
All others (none over 5%)	46,525		(299,654		)	4,553,133
Total	$	25,828,377	$	43,062,021		$	45,676,297

The negative revenue in 2012 reflects an increase in the reserve for sales returns sales made in previous years.

Revenue by Product

The following table sets forth the breakdown of the Company's consolidated net revenues, consisting of sales, royalty and licensing income, by revenue source for each product accounting for 10% or more of consolidated revenues in any of the three years ended December 31:



	2012		2011			2010
CRINONE®	$	22,045,871	$	17,807,014		$	21,249,096
Actavis Royalties and Deferred Revenue Recognition	3,079,379		24,625,204			18,118,833
RepHresh®	—		—			1,971,981
Replens®	—		662			1,815,365
STRIANT®	84,602		454,453			1,293,416
PROCHIEVE®	100,000		(284,521		)	716,872
Other	518,525		459,209			510,734
Total	$	25,828,377	$	43,062,021		$	45,676,297